Drug Trial Radar · NCT05384626
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
840
Planned (sponsor's estimate)
Start
Jun 9, 2022
Primary completion
Dec 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Nuvalent Inc.Industry
- Sponsor type
- Industry
- First posted
- May 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. Phase 1 will evaluate the overall safety and tolerability of neladalkib and will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of neladalkib in patients with advanced ALK+ solid tumors. Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of neladalkib at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of neladalkib in patients with advanced ALK-positive NSCLC and other solid tumors. A drug-drug interaction (DDI) sub-study will determine the effect of neladalkib on the pharmacokinetics of midazolam and repaglinide, as well as the effect of itraconazole on the pharmacokinetics of neladalkib, in patients with advanced ALK-positive NSCLC
Conditions
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
Interventions
Neladalkib (NVL-655)Drug
Oral Tablet of Neladalkib (NVL-655)
MidazolamDrug
Oral Solution of Midazolam
RepaglinideDrug
Oral Tablet of Repaglinide
ItraconazoleDrug
Oral Solution of Itraconazole
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicities (DLTs) (Phase 1)Time frame: Within the first 21 days of the first neladalkib (NVL-655) dose
- Recommended Phase 2 Dose (RP2D) (Phase 1)Time frame: Within 21 days of last patient dosed during escalation
- Objective Response Rate (ORR) (Phase 2)Time frame: 2-3 years after first patient dosed.
- Number of participants with treatment-emergent adverse events, as assessed by CTCAE, V5.0 (Phase 1)Time frame: Approximately 3 years
- Area under the curve of repaglinide (Phase 2 DDI sub-study)Time frame: Pre-dose and up to 24 hours post-dose
- Area under the curve of midazolam (Phase 2 DDI sub-study)Time frame: Pre-dose and up to 24 hours post-dose
- Area under the curve of neladalkib (NVL-655) (Phase 2 DDI sub-study)Time frame: Pre-dose and up to 24 hours post-dose
Locations
74 sites in 15 countries. Site status is shown where the registry gives one.
University of California Irvine Medical Center
Orange, California · Recruiting
University of California, Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Stanford Cancer Institute
Stanford, California · Recruiting
University of Colorado Cancer Center
Aurora, Colorado · Recruiting
Georgetown University Medical Center
Washington D.C., District of Columbia · Recruiting
University of Miami; Sylvester Cancer Center
Miami, Florida · Recruiting
Winship Cancer Institute, Emory University
Atlanta, Georgia · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
John Hopkins University
Baltimore, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Henry Ford Cancer Institute
Detroit, Michigan · Recruiting
Washington University School of Medicine Siteman Cancer Center
St Louis, Missouri · Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
OSU Brain & Spine Hospital
Columbus, Ohio · Recruiting
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania · Recruiting
Sarah Cannon
Nashville, Tennessee · Recruiting
MD Anderson Cancer Center
Houston, Texas · Active not recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Royal North Shore Hospital
Sydney, New South Wales, Australia · Recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Universitair Ziekenhuis Antwerpen (UZA)
Antwerp, Belgium · Recruiting
Universitaire Ziekenhuizen Leuven Campus Gastthuisberg
Leuven, Belgium · Recruiting
Cross Cancer Institute
Edmonton, Alberta, Canada · Recruiting
BC Cancer Center
Vancouver, British Columbia, Canada · Recruiting
The Ottawa Hospital Cancer Center
Ottawa, Ontario, Canada · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Centre Leon Berard
Lyon, France · Recruiting
Chu De Nantes
Nantes, France · Recruiting
Institut Claudius Regaud
Toulouse, France · Recruiting
Institute Gustave Roussy
Villejuif, France · Recruiting
Universitatsklinikum Koln - University Hospital Cologne
Cologne, Germany · Recruiting
Universitätsklinikum Frankfurt
Frankfurt, Germany · Recruiting
LungenClinic Grosshansdorf GmbH
Großhansdorf, Germany · Recruiting
Universkitatsklinikum Heidelberg - University Hospital Heidelberg
Heidelberg, Germany · Recruiting
Azienda Ospedaliera Universitaria Ospedali Riuniti Umberto
Ancona, Italy · Recruiting
IRCCS Istituto Tumori "G. Paolo II"
Bari, Italy · Recruiting
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.